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a b s t r a c t 
Background: This study investigated the immunogenicity and impact on nasopharyngeal carriage of a 
single dose of PCV10 given to 18-month-old Vietnamese children. This information is important for coun- 
tries considering catch-up vaccination during PCV introduction and in the context of vaccination during 
humanitarian crises. 
Methods: Two groups of PCV-naïve children within the Vietnam Pneumococcal Project received PCV10 
(n = 197) or no PCV (unvaccinated; n = 199) at 18 months of age. Blood samples were collected at 18, 19, 
and 24 months of age, and nasopharyngeal swabs at 18 and 24 months of age. Immunogenicity was as- 
sessed by measuring serotype-specific IgG, opsonophagocytosis (OPA) and memory B cells (Bmem). Pneu- 
mococci were detected and quantified using real-time PCR and serotyped by microarray. 
Findings: At 19 months of age, IgG and OPA responses were higher in the PCV10 group compared with 
the unvaccinated group for all PCV10 serotypes and cross-reactive serotypes 6A and 19A. This was sus- 
tained out to 24 months of age, at which point PCV10-type carriage was 60% lower in the PCV10 group 
than the unvaccinated group. Bmem levels increased between 18 and 24 months of age in the vaccinated 
group. 
Interpretation: We demonstrate strong protective immune responses in vaccinees following a single dose 
of PCV10 at 18 months of age, and a potential impact on herd protection through a substantial reduction 
in vaccine-type carriage. A single dose of PCV10 in the second year of life could be considered as part of 
catch-up campaigns or in humanitarian crises to protect children at high-risk of pneumococcal disease. 
© 2021 The Author(s). Published by Elsevier Ltd. 
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. Evidence before this study 
Infant vaccination with pneumococcal conjugate vaccine (PCV) 
s a proven strategy to reduce vaccine-type pneumococcal carriage 
nd disease. Infant PCV introduction may or may not be coupled 
ith catch-up vaccination in older children. Modelling studies from 
ietnam and Kenya suggest that the addition of catch-up vaccina- 
ion to infant PCV introduction accelerates both direct and indi- 
ect protection effects. PCV vaccination could also be an impor- 
ant strategy to protect older children affected by humanitarian 
rises and other emergency settings. The World Health Organiza- 
ion (WHO) currently recommends PCV catch-up vaccination cam- 
aigns in older children but notes that there is a lack of data to 
etermine whether one or two doses should be given during the 
econd year of life. We searched PubMed to 28 th February 2021 us- 
ng search terms including but not limited to “pneumococcal con- 
ugate vaccine”, “catch-up vaccination”, “toddler”, “older children”, 
humanitarian”, “immunogenicity” and “carriage”. Three trials re- 
ort immunogenicity data after one dose of PCV in the second year 
f life: two using PCV13 and one using PCV10. A trial from Burk- 
na Faso and a multicentre meningococcal vaccine trial both found 
hat a single dose of PCV13 among children aged 12-15 months 
as immunogenic for most serotypes. A trial from Kenya found 
hat a single dose of PCV10 among children 1-4 years of age re- 
uced vaccine-type pneumococcal carriage and showed good im- 
unogenicity, noting however that immune responses were lower 
mong children aged 12-23 months than those aged 24-59 months 
or five serotypes. More data are needed to facilitate decision- 
aking on optimal catch-up campaigns as part of infant PCV vac- 
ine introduction as well as formulating recommendations for PCV 
se during humanitarian crises. 
. Added value of this study 
This study is the first from Asia to evaluate a single PCV10 
ose in the second year of life, and the first study providing vac- 
ination at 18 months of age. We undertook a comprehensive as- 
essment of PCV10 immunogenicity including serotype-specific IgG 
nd opsonophagocytic assays (OPA) to all ten vaccine serotypes as 
ell as the cross-reactive serotypes 6A and 19A. We also mea- 
ured serotype-specific memory B cell responses (Bmem) to sev- 
ral serotypes as an indicator of long-term protection. Nasopha- 
yngeal carriage of pneumococcal bacteria was measured by qPCR 
ombined with molecular serotyping by microarray. Using this ap- 
roach, we demonstrated that a single dose of PCV10 at 18 months 
f age produced robust immunogenicity in terms of IgG and OPA 
esponses for all vaccine serotypes compared with unvaccinated 
hildren that persisted for six months. Bmem levels were higher 
fter six months for two serotypes (1 and 18C). By 24 months 
f age, there was a 60% reduction in vaccine-type pneumococ- 
al carriage. We also show a disconnect between IgG and OPA 
esponses for serotypes 1, 5 and 6B after a single PCV10 dose; 
erotypes 1 and 5 are common causes of invasive pneumococcal 
isease, particularly in Africa, while serotype 6B is a common car- 
iage serotype globally. OPA is regarded as a better marker of pro- 
ection. 
. Implications of all the available evidence 
Results from this study are consistent with previous data from 
ther parts of the world and support the use of a single dose of 
CV10 as part of catch-up campaigns associated with infant PCV 
accination as well as for campaigns in high-risk settings such as 
umanitarian crises. Our data suggest that protection will extend 
eyond the second year of life, covering a time when risk of in- 
ection and particularly transmission are high. In regions where 2 erotypes 1 and 5 are dominant, a second dose might be consid- 
red to improve the disconnect between IgG and OPA responses, 
s has been reported previously. This information will be impor- 
ant for countries considering catch-up campaigns as part of PCV 
ntroduction as well as informing recommendations for the use of 
CV in emergency settings. 
. INTRODUCTION 
Streptococcus pneumoniae (the pneumococcus) is a leading cause 
f mortality and morbidity in children less than five years of age 
orldwide. [1] The introduction of pneumococcal conjugate vac- 
ines (PCVs) into routine infant immunisation schedules has led to 
 decline in vaccine-type (VT) pneumococcal disease. [2-4] PCVs re- 
uce pneumococcal disease by eliciting serotype-specific antibody 
esponses and by reducing VT nasopharyngeal carriage, which 
eads to reduced pneumococcal transmission and herd protection 
n the broader population. Modelling studies from Vietnam [5] and 
enya [6] suggest that coupling infant PCV introduction with catch- 
p vaccination among older children accelerates both direct and 
ndirect protection, but there is limited empirical evidence to sup- 
ort this. The World Health Organization (WHO) recommends the 
se of catch-up vaccination at the time of PCV introduction wher- 
ver possible, noting that there are currently not enough data to 
etermine whether two doses are required for children aged 12 
o 23 months, as recommended by the manufacturers, or whether 
ne dose is sufficient. [7] 
Only three trials have reported immunogenicity data following 
 single dose of PCV in the second year of life. Strong immune 
esponses were seen three months after a dose of 13-valent PCV 
PCV13; Prevnar-13 ®, Pfizer) administered at 12-15 months of age 
n Burkina Faso [8] , and one month after a dose administered at 12- 
4 months of age in a multicentre meningococcal vaccine trial. [9] A 
rial of ten-valent PCV (PCV10; Synflorix ®, GlaxoSmithKline Biolog- 
cals) among children aged 1-4 years in Kenya showed that a single 
ose provided good immunogenicity one-month post-vaccination 
nd also reduced vaccine-type pneumococcal carriage two-months 
ost-vaccination. [10] 
PCV vaccination in older children could also be an important 
ublic health tool for populations affected by humanitarian crises 
nd in other emergency settings, particularly famine where mal- 
ourished children are at very high risk of death from pneumo- 
ia.[ 11 , 12 ] WHO recommends that, during emergency situations, 
CV is used in children under one and considered for use in chil- 
ren under five, although there are no clear guidelines on the 
arget age, number of doses or frequency of campaigns due to a 
ack of evidence.[ 13 , 14 ] The COVID-19 pandemic has profoundly af- 
ected nutrition and vaccine access for the poorest children in the 
orld[ 15 , 16 ]. Whilst nonpharmaceutical interventions introduced 
uring the pandemic may reduce transmission of other respiratory 
athogens [17] , post-pandemic there is likely to be a large pop- 
lation of increasingly vulnerable, unvaccinated children at high 
isk of pneumonia. A single dose of PCV to high-risk children 18 
onths and older in the most difficult of settings has the potential 
o protect those children and their communities. 
A single dose of PCV during the second year of life could ac- 
elerate the impact of PCV introduction and could provide a feasi- 
le and cost-effective approach to protect vulnerable populations 
uring emergency situations. However, immunogenicity and car- 
iage data to support this approach are limited. In Vietnam, PCV 
s not currently part of the routine infant immunisation program, 
nabling evaluation of a single dose approach among unvaccinated 
hildren. We assessed the immunogenicity and impact on car- 
iage of a single dose of PCV10 at 18 months of age as part of a
arger trial of different infant pneumococcal vaccination schedules 
n Vietnamese children. We previously reported that pneumococ- 











































































































al carriage among unvaccinated participants peaked at 24.5% at 12 
onths of age with a similar prevalence of 23.9% at 18 months of 
ge, [18] suggesting the value of strategies to protect children dur- 
ng the second year of life. We measured immune responses in- 
luding serotype-specific IgG, opsonophagocytosis and memory B 
ells (Bmem) in vaccinated and unvaccinated children, as well as 
neumococcal carriage rates and density. 
. METHODS 
.1. Study design 
This study was part of the Vietnam Pneumococcal Project, the 
rotocol for which has been published previously. [14] The study 
as approved by the Institutional Review Board at the Pasteur In- 
titute of Ho Chi Minh City and ethical approval was obtained from 
he Human Research Ethics Committee of the Northern Territory 
epartment of Health and Menzies School of Health Research, Aus- 
ralia and the Vietnam Ministry of Health Ethics Committee. The 
linical trial registration number is NCT01953510. 
The Vietnam Pneumococcal Project involved 1201 infants ran- 
omised at 2 months of age to one of six infant PCV schedules 
nd 199 children recruited at 18 months of age. [14] This current 
tudy involves one of the groups enrolled at 2 months of age, who 
eceived a first dose of PCV10 at 18 months of age (PCV10 group), 
nd the group enrolled at 18 months of age as unvaccinated con- 
rols (unvaccinated group). Participants were recruited from Dis- 
ricts 4 and 7 in Ho Chi Minh City, Vietnam, with the unvacci- 
ated group recruited in parallel when the PCV10 group partici- 
ants were reaching 18 months of age. Both groups were followed 
p to 24 months of age, at which point they received a dose of 
CV10. 
.2. Study procedures and laboratory analyses 
Blood samples were collected at 18, 19 and 24 months of 
ge for immunogenicity assessments. A modified WHO ELISA 
ethod [19] was used to measure serotype-specific IgG levels to 
ll PCV10 serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), as
ell as the cross-reactive serotypes 6A and 19A, at all time points. 
psonophagocytic assays (OPA) for these 12 serotypes were per- 
ormed in a subset of participants (the first 50 paired samples per 
roup) at the 19 and 24 month time points, using a previously 
ublished multiplexed OPA method [13] with some minor modifi- 
ations. Peripheral blood mononuclear cells (PBMCs) were isolated 
n a subset of participants (the first 100 recruited per group) at the 
8 and 24 month time points, for measurement of pneumococcal- 
pecific Bmem by ELISPOT for seven serotypes (1, 5, 6B, 14, 18C, 
9A and 23F) using an established method. [20] 
Nasopharyngeal swabs were collected at 18 and 24 months, and 
ere stored and transported consistent with WHO guidelines. [21] 
neumococcal detection and quantification was performed using 
eal-time quantitative PCR (qPCR) targeting the lytA gene. Molec- 
lar serotyping was conducted using DNA microarray as previously 
escribed. [22] 
.3. Outcomes 
Serotype-specific IgG responses by ELISA were summarised in 
erms of the proportion of children with IgG ≥0 • 35μg/ml and the 
eometric mean concentrations (GMCs) of IgG. Functional antibody 
esponses by OPA were summarised in terms of the proportion 
f children with an opsonisation index (OI) ≥8 and the geometric 
ean OIs (GMOIs). Serotype-specific Bmem levels were expressed 
s the mean number of antibody secreting cells (ASCs) per million 
BMCs. 3 Pneumococcal carriage was described in terms of overall 
arriage (all capsular pneumococci), VT-carriage (carriage of a 
erotype contained in the PCV10 vaccine), non-VT-carriage (car- 
iage of a serotype not in the PCV10 vaccine, excluding non- 
ncapsulated pneumococci), and serotype 6A or 19A carriage. 
erotype ‘11F-like’ was reported as 11A, [23] and serotypes 15B and 
5C were reported as 15B/C as these serotypes interconvert. [24] 
neumococcal density (determined by lytA qPCR) was multiplied 
ith the relative abundance of the serotype in the sample (deter- 
ined by microarray) to determine serotype-specific density. 
.4. Statistical Analysis 
The proportions of vaccinated and unvaccinated children with 
 serotype-specific IgG concentration ≥0 • 35μg/ml at 18 months 
f age, four weeks post-vaccination (19 months of age), and six 
onths post-vaccination (24 months of age) were compared using 
 two-sided Fisher’s exact test. The same analysis was performed 
or the proportion of children with OI ≥8 at the 19 and 24 month 
ime points. 
Serotype-specific IgG concentrations and OIs for all serotypes 
ere log 10 -transformed to calculate GMCs and GMOIs with 95% CI, 
espectively. Groups were compared using a two-sample unpaired 
-test. The mean ASCs per million PBMCs with 95% CI were com- 
ared between groups at 18 and 24 months using a two-sample 
npaired t-test. A pre/post comparison of the mean ASCs were also 
ompared between 18 and 24 months within each group using a 
wo-sample paired t-test. 
Carriage prevalence was compared between groups using a 
wo-sided Fisher’s exact test. Density data for pneumococcal car- 
iers were log 10 -transformed and reported as log 10 genome equiv- 
lents per ml (log 10 GE per ml). As the transformed density data 
ere not normally distributed, groups were compared using the 
on-parametric Mann-Whitney U-test. 
Statistical analyses were conducted using GraphPad Prism ver- 
ion 7 • 04 (GraphPad Software, Inc.) and Stata version 14 • 2 (Stata-
orp LLC). For all comparisons, a 0.05 alpha level was used when 
valuating strength of evidence for differences between groups. 
.5. Role of funding source 
The funders of the study had no role in the study design, data 
ollection, data analysis, data interpretation, or writing of the re- 
ort. The corresponding author had full access to all the data in 
he study and had final responsibility for the decision to submit 
or publication. 
. RESULTS 
Between 30 September 2013 and 9 January 2015, 197 infants 
ere enrolled at two months of age and allocated to receive a sin- 
le dose of PCV10 at 18 months of age as part of the Vietnam 
neumococcal Project. Between 14 April 2015 and 12 May 2016, 
99 children were recruited at 18 months of age as an unvac- 
inated control group ( Figure 1 ). Participant characteristics were 
imilar between groups except for the median age and antibiotic 
se for the past fortnight at the 18 month visit ( Table 1 ). 
At 18 months of age, prior to PCV10, there were no differ- 
nces in the proportion of children with serotype-specific IgG 
0 • 35μg/ml or the IgG GMCs between the groups ( Figure 2 , Ap-
endix Table S1). At this time, antibody levels were low for most 
erotypes, although over half the participants in each group had 
gG ≥0 • 35μg/ml for serotypes 5, 19F, 6A, and 19A ( Figure 2 , Ap-
endix Tables S1 and S2). At 19 months of age, four weeks af- 
er a single dose of PCV10, the proportion of children with IgG 
0 • 35μg/ml and the IgG GMCs were higher in the vaccinated 
R.A. Higgins, B. Temple, V.T.T. Dai et al. The Lancet Regional Health - Western Pacific 16 (2021) 100273 
Figure 1. Trial Profile. Blood samples not included in analyses were due to no sample obtained (n = 11, includes both participants who missed the study visit and participants 
who attended the visit but had no sample collected), insufficient volume collected (n = 2) or excluded as a result of a protocol violation (PCV10 administered outside the trial, 
n = 1). Nasopharyngeal swabs that were not included in analyses were due to insufficient DNA for microarray (n = 15), no sample obtained (n = 5, includes both participants 
who missed the study visit and participants who attended the visit but had no sample collected), pneumococcal carriage status was unable to be determined (n = 3) or 
excluded as a result of a protocol violation (PCV10 administered outside the trial or sample collected after administration of PCV10, n = 2). 
4 
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Table 1 
Participant characteristics by study group 
PCV10(Group F) Unvaccinated (Group G) P-value ∗
N at enrolment 197 199 
District, 7 ‡ 110/197 (55.8%) 92/199 (46.2%) 0.056 
Age at enrolment (months) 2.1 (1.9-2.5) 18.3 (17.4-20.3) NA 
Sex, female 97/197 (49.2%) 86/199 (43.2%) 0.229 
Birthweight (g) † 3208 (395) 3264 (423) 0.326 
Hospital-based delivery † 144/197 (73.1%) 152/198 (76.8%) 0.400 
Delivery by elective caesarean † 34 /196 (17.3%) 44/196 (22.4%) 0.206 
Cigarette smoker in house 125/197 (63.5%) 129/199 (64.8%) 0.776 
N at 18 month visit 185 197 
Age at 18 month visit (months) 18.1 (17.9-19.9) 18.3 (17.4-20.3) < 0.001 
Any current breastfeeding † 21/184 (11.4%) 32/197 (16.2%) 0.173 
Presence of URTI symptoms † 28/184 (15.2%) 31/197 (15.7%) 0.889 
Antibiotic use in past fortnight † 20/184 (10.9%) 40/197 (20.3%) 0.012 
Current antibiotic use † 10/184 (5.4%) 8/197 (4.1%) 0.528 
Data are n/N (%), median (range) or mean (SD). 
∗P-values based on chi-squared test (for comparisons of proportions), Wilks’ lambda (for compar- 
isons of means), or quantile regression (for comparisons of medians). 
† Data not available for all participants. ‡ Participants were recruited from two districts in Ho 

















































































s  roup than the unvaccinated group for all PCV10 and cross-reactive 
erotypes ( Figure 2 , Appendix Table S2). For eight out of ten 
CV10 serotypes, 94-100% of vaccinated children had IgG levels 
0 • 35μg/ml, with 80% for serotype 6B and 84% for serotype 23F. A 
imilar trend was found for OPA, where the vaccinated group had a 
igher proportion of children with OI ≥8 and higher GMOIs for all 
2 serotypes at 19 months of age compared with the unvaccinated 
roup ( Figure 3 , Appendix Table S3). 
By 24 months of age, six months after a single dose of PCV10, 
he proportions of children with IgG ≥0 • 35μg/ml were still higher 
n the vaccinated group compared with the unvaccinated group for 
ll serotypes except the cross-reactive serotype 6A ( Figure 2 ). The 
gG GMCs were also higher in vaccinated children (compared with 
nvaccinated children) for all serotypes tested. Similarly, the pro- 
ortions of children with OI ≥8 and GMOIs remained higher in the 
accinated group, compared with the unvaccinated group, for all 
2 serotypes ( Figure 3 , Appendix Table S4). 
For some serotypes, the IgG and OPA responses were not al- 
ays concordant. At 19 months of age, 99% of vaccinated children 
ad IgG ≥0 • 35μg/ml for serotype 1, whilst only 67% had OI ≥8
ollowing a single dose of PCV10. This pattern was also observed 
or serotypes 5 and 6B, where 99% and 80% of vaccinated children 
ad IgG ≥0 • 35μg/ml but only 65% and 48% of vaccinated children 
ad OIs ≥8, respectively. This was also seen for the cross-reactive 
erotypes 6A in vaccinated children (85% with IgG ≥0 • 35μg/ml and 
nly 33% with OIs ≥8) and to a lesser extent for serotype 19A (96%
ith IgG ≥0 • 35μg/ml and 71% with OI ≥8, Figure 2 A and 3 A, Ap-
endix Tables S1 and S3). 
There were no differences in the levels of pneumococcal- 
pecific Bmem between the groups prior to vaccination at 18 
onths of age for any of the seven serotypes tested ( Table 2 ). At
4 months, pneumococcal-specific Bmem were generally higher in 
accinated children compared with unvaccinated children, but this 
as only significant for serotypes 1 and 18C ( Table 2 ). However, 
mem levels increased between 18 and 24 months of age in vac- 
inated children for all serotypes except 19A, while there were no 
ifferences in Bmem levels between 18 and 24 months in unvacci- 
ated children. 
The prevalence of capsular pneumococcal carriage was simi- 
ar in both groups at 18 months of age (25% in the vaccinated 
roup compared with 23% in the unvaccinated group; Table 3 ). 
here were also no differences in VT carriage, non-VT carriage, 
r carriage of serotypes 6A/19A between groups at this time 
oint ( Table 3 ). At 18 months of age, the most commonly carried 
erotypes were 19F, 23F, 6B and 6A (Appendix Table S5). At 24 t
5 onths of age, VT carriage was 60% lower in the vaccinated group 
ompared with the unvaccinated group (5.0% vs. 12.4%, Table 3 ). 
his led to a 35% reduction in all capsular pneumococcal carriage, 
lthough this did not reach statistical significance. There were no 
ifferences between groups at 24 months of age in relation to non- 
T or serotype 6A/19A carriage. Pneumococcal density among car- 
iers did not differ between groups at either 18 or 24 months of 
ge, in terms of overall density, VT density or non-VT density (Ap- 
endix Figure S1). 
. DISCUSSION 
There are no specific recommendations for the optimal use of 
CVs during the second year of life, either for catch-up vaccina- 
ion (as part of national PCV introduction) or during humanitar- 
an crises and other emergency settings, due to a paucity of data. 
ere we found that a single dose of PCV10 at 18 months of age 
nduced strong antibody responses by ELISA to all vaccine and 
ross-reactive serotypes, and strong functional antibody responses 
y OPA to most serotypes. These responses lasted for at least six 
onths. We also found an increase in Bmem levels and a large re- 
uction in VT carriage at 24 months in children vaccinated with a 
ingle dose of PCV10. 
Previous data on responses to a single dose of PCV in the 
econd year of life are limited. In Kenya, immune responses to 
wo doses of PCV10 administered 2-6 months apart were inves- 
igated among children aged 12-59 months. [10] Over 90% of par- 
icipants aged 12-23 months had protective levels of antibody to 
ve serotypes after a single dose. The same was true for eight 
erotypes (all except 6B and 23F) among children aged 24-59 
onths, and GMCs were also higher in the 24-59 month group 
ompared with the 12-23 month group for five serotypes. In a 
ecent study in Burkina Faso, over 90% of participants had pro- 
ective levels of antibody to all serotypes except 3, 6B and 23F 
hree months following a single dose of PCV13 at 12-15 months 
f age. [8] Similarly, a multicentre trial of meningococcal vaccine 
hat also measured responses to a single dose of PCV13 at 12-14 
onths of age found protective levels of antibody to all serotypes 
xcept serotype 3 in over 90% of participants. [9] These findings 
re broadly consistent with our data, in which over 90% of par- 
icipants had protective levels of antibody to most serotypes. Ex- 
eptions were 6B and 23F, although lower correlates of protection 
ave been proposed for these serotypes [25] . Together these results 
uggest that a single dose of PCV in the second year of life is likely
o be protective for most serotypes. 
R.A. Higgins, B. Temple, V.T.T. Dai et al. The Lancet Regional Health - Western Pacific 16 (2021) 100273 
Figure 2. Comparison of serotype-specific IgG responses between vaccinated and unvaccinated children. (A) The proportion of children achieving serotype-specific IgG 
≥0 • 35μg/mL and (B) Geometric mean concentration (GMCs) of serotype-specific IgG at 18, 19 and 24 months of children who received PCV10 at 18 months of age or who 
were unvaccinated. Bars represent 95% CIs. P-values were calculated using a two-sided Fisher’s exact test to examine difference in proportions (A) and unpaired two-sided 































A single dose of PCV10 resulted in an increase in Bmem lev- 
ls between 18 and 24 months of age for all six vaccine serotypes 
ested. Limited data exist on Bmem levels after primary vaccination 
ith PCVs in infants and children but those few studies that inves- 
igated the effect of PCVs on Bmem also show an increase in lev- 
ls after vaccination[ 20 , 26-28 ]. From other groups within the Viet- 
am Pneumococcal Project, a primary series vaccination of PCV10 
r PCV13 induced high levels of serotype-specific Bmem. [27] An- 
ther study that compared the effect of a single dose of PCV7 in 
aïve adults and toddlers (aged 12 months) found a significant in- 
rease in memory B cells by day seven post-vaccination in both 
roups. [26] In Kenyan toddlers 12-23 months of age, a single dose 
f PCV10 generated higher Bmem one month after vaccination for 
erotypes 1 and 19F. [29] Although we did not assess Bmem levels 
t their peak (seven days post-vaccination), we were still able to 
bserve an increase in Bmem numbers after six months for all vac- 6 ine serotypes tested in the PCV10 group that was not seen in the 
nvaccinated group. This suggests that a single dose of PCV10 in- 
uces immunological memory responses that are likely to be pro- 
ective for up to six months post-vaccination. 
A single dose of PCV10 at 18 months led to a dramatic 60% re- 
uction in VT carriage at 24 months of age compared with unvac- 
inated controls. This is consistent with the Kenya trial in which 
hildren aged 12-59 months who received one dose of PCV10 had 
pproximately 30% lower VT carriage compared with unvaccinated 
ontrols after six months, although this was not statistically sig- 
ificant. [10] Children between the ages of 12 and 36 months have 
een shown to be the key transmitters of pneumococci;[ 30 , 31 ] any
eduction in carriage in this age group therefore has the potential 
o generate significant herd protection. Whether a single PCV dose 
ould have a similar impact in settings where carriage and/or dis- 
ase rates are higher is unknown and should be addressed in fu- 
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Figure 2. Continued 
Table 2 
Serotype-specific memory B cell (Bmem) levels in children who received PCV10 at 18 months of age or who were unvaccinated. 
18 months 24 months 18 months vs 24 months 






(Group F, n = 74) 
Unvaccinated 
(Group G, n = 92) P-value ∗
PCV10 
(Group F, n = 70) 
Unvaccinated 
(Group G, n = 82) P-value ∗ P-value † P-value ‡ 
PCV10 serotypes 
1 1.34(0.77 – 1.90) 1.67(1.04 – 2.31) 0.445 2.99(2.18 – 3.79) 1.48(0.88 – 2.08) 0.003 0.002 0.569 
5 1.19(0.71 – 1.67) 1.73(1.09 – 2.37) 0.200 2.36(1.67 – 3.04) 1.90(1.19 – 2.61) 0.365 0.006 0.944 
6B 0.82(0.48 – 1.17) 1.46(0.96 – 1.96) 0.050 1.73(1.16 – 2.30) 1.24(0.69 – 1.79) 0.227 0.008 0.928 
14 1.28(0.76 – 1.81) 1.82(1.12 – 2.53) 0.240 2.94(2.13 – 3.75) 2.06(1.24 – 2.88) 0.134 0.001 0.603 
18C 1.16(0.66 – 1.66) 1.92(1.30 – 2.54) 0.067 7.54(5.19 – 9.89) 2.46(1.66 – 3.27) < 0.001 < 0.001 0.358 
23F 1.46(0.96 – 1.96) 2.03(1.46 – 2.61) 0.148 2.43(1.76 – 3.09) 2.55(1.73 – 3.37) 0.824 0.025 0.179 
Cross-reactive serotype 
19A 1.10(0.66 – 1.53) 1.83(1.24 – 2.41) 0.058 1.70(1.17 – 2.23) 1.71(1.06 – 2.35) 0.986 0.055 1.00 
∗ P-values were calculated using unpaired two-sided t-test to examine the difference between groups. 
† P-values and 
‡ P-values were calculated using paired two-sided t-test to examine the difference between time points for the vaccinated group and unvaccinated group, respectively. 
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Figure 3. Comparison of OPA responses between vaccinated and unvaccinated children. (A) The proportions of children achieving opsonisation index (OI) ≥8 and (B) 
Geometric mean opsonisation indices (GMOIs) at 19 and 24 months of children who received PCV10 at 18 months of age or who were unvaccinated. Bars represent 95% CIs. 
































ure studies. However, in situations where only one dose can only 
e given (emergency settings or catch-up campaigns), a single dose 
f PCV is likely to be of benefit. 
The use of both ELISA and OPA assays in this study revealed 
 discordance in the responses to some serotypes. Serotypes 1, 5, 
B and the cross-reactive serotype 6A were all poorly immuno- 
enic by OPA, similar to previous studies.[ 5 , 32 ] We have previously
hown that poor OPA responses to serotype 1 post-primary se- 
ies can occur despite strong ELISA responses, although this was 
orrected following a booster dose. [32] This is consistent with the 
enya trial, which found that a second dose of PCV10 was required 
o bring OI ≥8 above 80% for serotypes 1, 5, 6B, 14 and 19F. As
PA may be a better marker of protection, a second dose might 
e considered to improve the disconnect between IgG and OPA 
esponses, such as in African settings where serotype 1 disease 
s high. 8 The high cost associated with PCVs remains a major imped- 
ment for their use in humanitarian immunisation programs. [11] 
ased on our findings, a single dose of PCV10 at 18 months could 
e effective during emergency situations to protect children liv- 
ng in extremely vulnerable conditions where multi-dose vaccina- 
ion is not feasible. Such an approach has been successfully used 
ith measles supplementary immunisation campaigns, wherein 
xpanded target-age groups allowed for catch-up immunisations 
nd a reduced dosing schedule. [33] Our findings also suggest that 
 single dose of PCV10 in the second year of life could also be con-
idered for catch-up vaccination programs as part of infant PCV 
ntroduction. As the interest in reduced-dose PCV schedules in- 
reases following the recent introduction of a 1 + 1 schedule in the 
K [34] , the role of catch-up programs is likely to become increas- 
ngly important for maximising the impact of vaccine introduc- 
ion. Catch-up campaigns are also crucial for extending protection 
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Figure 3. Continued 
Table 3 
Pneumococcal carriage prevalence (%) at 18 and 24 months of age in children who received PCV10 at 18 months of age or who were unvaccinated. 
18 months 24 months 
PCV10(Group F, n = 176) Unvaccinated(Group G, n = 192) PCV10(Group F, n = 161) Unvaccinated(Group G, n = 170) 
Prevalence (%) P-value ∗ Prevalence (%) P-value ∗
All capsular pneumococci 25.0(18.8-32.1) 22.9(17.2-29.5) 0.714 13.7(8.8-20.0) 21.2(15.3-28.1) 0.083 
PCV10 carriage 13.1(8.5-19.0) 15.1(10.4-21.0) 0.654 5.0(2.2-9.6) 12.4(7.8-18.3) 0.020 
Non-PCV10 carriage 13.1(8.5-19.0) 8.3(4.8-13.2) 0.175 9.9(5.8-15.6) 10.6(6.4-16.2) 0.859 
6A/19A carriage 6.8(3.6-11.6) 4.2(1.8-8.0) 0.358 5.6(2.6-10.3) 6.5(3.3-11.3) 0.820 





















o older children who miss doses due to interruptions in routine 
mmunisation such as experienced in many countries due to the 
urrent COVID-19 pandemic. 
A limitation of this study was that the two groups were not re- 
ruited at the same time. However, they were recruited from the 
ame study sites, and few differences in participant characteris- 
ics between groups were observed at the 18 month visit. Antibi- 
tic use in the past fortnight was reported almost twice as fre- 
uently in the unvaccinated group than the PCV10 group, although 
eported current antibiotic use was similar between groups. Any 
ffect of increased antibiotic use in the unvaccinated group would 9 e to reduce the pneumococcal carriage rates and thus bias the 
esults towards no effect. Importantly, the immunological and car- 
iage data at 18 months of age did not differ between groups, and 
o the differences in participant characteristics are unlikely to have 
ffected our results. 
In conclusion, a single dose of PCV10 at 18 months of age was 
ighly immunogenic and produced functional immunity that was 
till detectable at 24 months of age for all vaccine serotypes. It was 
lso able to induce immunological memory and reduced VT car- 
iage in vaccinated children at 24 months of age. Together, these 
ata support the use of a single dose of PCV10 in the second year 












































































f life for catch-up vaccination and in emergency situations to pro- 
ide both individual and herd protection. 
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